Portfolio

We take a back-and-build approach to our investments, helping entrepreneurs access the human, intellectual, and financial resources needed to go the distance.

ADARx PharmaceuticalsRNA targeting platform focused on genetic, cardiometabolic and central nervous system diseases
Akamis LogoInnovative gene-based immuno-oncology treatments for solid tumors
Alios BiopharmaClinical stage company focused on developing therapies for viral diseases
AlumisClinical stage company developing next generation TYK2 inhibitors for autoimmune diseases
Ancora BiotechClinical stage biologic treatments for oncology and inflammatory diseases
GroupNovel, adaptive, controllable cell therapies for the treatment of patients with cancer and autoimmune diseases
ARS PharmaDeveloping an easy-to-use and needle-free epinephrine nasal spray to treat severe allergies
AsceneuronNovel, oral small molecule therapeutics for neurodegenerative diseases
Avalyn PharmaClinical stage company developing inhaled therapies to treat rare respiratory diseases
avenzo-logoCompany looking to in-license precision oncology assets with differentiated target product profiles
GroupA new class of small, chemically synthesized medicines for oncology and beyond
BiotheryxClinical-stage company leveraging Targeted Protein Degradation for novel therapeutics for oncology and inflammatory diseases
Codify TherapeuticsDiscovery stage biotech developing therapeutics exploiting alternative RNA splicing.
Combined ShapeTransformative gene-based medicines for serious human diseases
Decibel TherapeuticsGroundbreaking treatments to restore and improve hearing and balance
Design TherapeuticsNew class of molecules for degenerative disorders
dren-logoPlatform for selective depletion of disease-causing cells in oncology and other diseases
Econic BiosciencesDiscovery stage company targeting extrachromosomal DNA to power the next wave of cancer treatments.
effector-logoClinical stage oncology company pioneering a class of selective translation regulators
Fore BiotherapeuticsHighly selective medicines for functionally and genomically defined cancer patients
HotSpot TherapeuticsUnlocking nature's regulatory mechanisms to fuel the discovery of new medicines
IpierianNovel treatments for Tauopathies
Kartos TherapeuticsClinical stage company developing a MDM2 inhibitor- Navtemadlin- for the treatment of myelofibrosis
mineralys-logoClinical stage company developing a candidate for a targeted approach to hypertension
GroupAdvanced therapeutics for patients suffering from a range of autoimmune diseases
Mission TherapeuticsTargeting the ubiquitin pathway with a new class of drugs
Morphic TherapeuticA new generation of oral integrin therapies for the treatment of serious chronic diseases
nimbus-tx-logoPioneering technologically-driven methods of drug discovery, to make therapeutics against the most challenging of targets
nkarta-logoImproving upon the efficacy of cell therapy, making it more rapidly available to the broad population
nomic-logoA high-throughput proteomics platform to enable drug discovery
odyssey-tx-logoFocused on transforming lives of patients with immune dysfunctions and cancer
palleon-pharma-logoGlyco-sensing molecules designed to overcome resistance to first-generation immuno-oncology drugs
Pandion TherapeuticsTherapeutics for localized immunomodulation at the site of disease for patients with autoimmune and inflammatory disease
Principia BiopharmaOral treatments for immune diseases
GroupTaking a smarter approach to fertility and family building benefit solutions
PulmocideAdvanced inhaled anti-infectives for targeted treatment of life-threatening lung infections
Clinical stage company developing innovative therapeutics for renal diseases for Japanese and Asian patients
GroupPioneering the integrated mapping of disease networks for precision therapeutics
River RenalClinical stage company focused on orphan renal diseases
River VisionBiologic to treat the thyroid eye disease
Simcha TherapeuticsClinical stage company developing a novel IL-18 construct to treat oncology patients
spero-colour-logoFocused on identifying, developing and commercializing medicines for multi-drug resistant (MDR) bacterial infections and rare disease
Telios PharmaClinical stage company developing a novel targeted therapy to treat selected blood cancers and ophthalmology diseases
transquis-logoDiscovering innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases
True North TherapeuticsDevelop novel therapeutics for complement-mediated rare diseases
Targeted cancer therapies designed to address treatment resistance and improve lives
Xap TherapeuticsEarly stage company from the founders of CRISPR Therapeutics

NOTE: Referenced portfolio companies are provided for illustrative purposes only and this list may not be comprehensive, and it should not be assumed that any referenced portfolio companies were or will be profitable. Certain of these investments were made by the SR One team while part of the legacy business with GSK and are not in the Fund I or Fund II portfolios. Past performance is not a guarantee of future results. The views expressed on this website (a) are strictly those of SR One, (b) are for informational purposes only, (c) are not intended to provide a basis for evaluating any investment acquisition or disposition, (d) are not a recommendation of any particular investment or security, and (e) are not a recommendation to invest in any particular fund advised or managed by SR One.